AtriCure (NASDAQ: ATRC) — Perfil da empresa, notícias e dados financeiros
AtriCure develops innovative surgical devices for atrial fibrillation, emphasizing minimally invasive treatment options.
AtriCure
AtriCure (NASDAQ:ATRC) is a medical device company focused on developing, manufacturing, and selling innovative surgical devices designed to provide solutions for physicians treating atrial fibrillation and related conditions. Specializing in minimally invasive and open surgical ablation procedures, AtriCure aims to enhance patient outcomes by providing innovative technologies that meet the needs of cardiothoracic surgeons and patients alike. The company's portfolio includes a variety of devices and accessories used in surgery that address the growing global demand for less invasive medical treatments. AtriCure's primary mission is to reduce the worldwide prevalence of atrial fibrillation by improving existing treatment options and by investing in the development of new technologies that can offer better solutions for patients and healthcare providers.
Resumo
Operações
Produtos e/ou serviços de AtriCure
- AtriClip Left Atrial Appendage Exclusion System is designed to minimize stroke risk in cardiac surgery patients by securely closing off the left atrial appendage.
- OPEN Ablation portfolio, including the Isolator Synergy ablation system, offers tools for minimally invasive surgical ablation to treat atrial fibrillation (AFib) during cardiac surgery.
- EPi-Sense Guided Coagulation System with VisiTrax is used for managing persistent and long-standing persistent forms of atrial fibrillation through minimally invasive procedures.
- CryoForm Cryoablation System, a flexible device offering surgeons the ability to treat cardiac arrhythmias via a cold-based therapy during surgery.
- AtriSeal is a comprehensive line of products aimed at mechanically sealing soft tissue in a variety of cardiac surgical procedures.
- Heart Hospital of New Mexico at Lovelace Medical Center, a partnership focusing on the treatment and management of atrial fibrillation.
equipe executiva do AtriCure
- Michael H. CarrelCEO, President & Director
- Angela L. WirickChief Financial Officer
- Douglas J. SeithChief Operating Officer
- Salvatore PriviteraChief Technical Officer
- Justin J. NozneskyChief Marketing & Strategy Officer
- Vinayak DoraiswamyChief Scientific Officer
- Karl S. DahlquistChief Legal Officer
- Valerie Storch-WillhausVice President of Corporate Marketing & Communications
Principais indicadores financeiros
Resultados divulgados pela AtriCure, em USD.
- Cap. de mercado
- 3,1 bi
- Receita (TTM)
- 569,6 mi
- P/L
- 292.5
- LPA (diluído, TTM)
- 0.2
- Dividend yield
- —
- Margem de lucro
- 1.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 534,5 mi | -3,4 mi | -11,4 mi | |
| 465,3 mi | -40 mi | -44,7 mi | |
| 399,2 mi | -26,7 mi | -30,4 mi | |
| 330,4 mi | -42,7 mi | -46,5 mi |